- Home
- KALA vs ONCO Comparison
KALA vs ONCO Comparison
Compare KALA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- ONCO
- Stock Information
- Founded
- KALA 2009
- ONCO 2018
- Country
- KALA United States
- ONCO United States
- Employees
- KALA N/A
- ONCO N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- ONCO Health Care
- Exchange
- KALA Nasdaq
- ONCO Nasdaq
- Market Cap
- KALA 5.1M
- ONCO 4.3M
- IPO Year
- KALA 2017
- ONCO 2022
- Fundamental
- Price
- KALA $0.66
- ONCO $2.46
- Analyst Decision
- KALA Buy
- ONCO
- Analyst Count
- KALA 3
- ONCO 0
- Target Price
- KALA $31.50
- ONCO N/A
- AVG Volume (30 Days)
- KALA 244.4K
- ONCO 30.2K
- Earning Date
- KALA 11-07-2025
- ONCO 11-13-2025
- Dividend Yield
- KALA N/A
- ONCO N/A
- EPS Growth
- KALA N/A
- ONCO N/A
- EPS
- KALA N/A
- ONCO N/A
- Revenue
- KALA N/A
- ONCO $1,223,751.00
- Revenue This Year
- KALA N/A
- ONCO N/A
- Revenue Next Year
- KALA N/A
- ONCO N/A
- P/E Ratio
- KALA N/A
- ONCO N/A
- Revenue Growth
- KALA N/A
- ONCO N/A
- 52 Week Low
- KALA $0.64
- ONCO $2.10
- 52 Week High
- KALA $20.60
- ONCO $179.35
- Technical
- Relative Strength Index (RSI)
- KALA 27.23
- ONCO 35.96
- Support Level
- KALA $0.64
- ONCO $2.67
- Resistance Level
- KALA $0.73
- ONCO $2.90
- Average True Range (ATR)
- KALA 0.06
- ONCO 0.25
- MACD
- KALA 0.32
- ONCO -0.08
- Stochastic Oscillator
- KALA 31.24
- ONCO 20.90
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.